
zzso zzso zzso a novel, oral zzso zzso blocks zzso and zzso zzso zzso in the tumor and zzso zzso demonstrated zzso activity in Phase I studies, and was tolerated and inhibited tumor growth in combination with zzso in zzso zzso This Phase I zzso study determined the safety, zzso and efficacy of zzso plus zzso 

Thirty-four patients with zzso solid tumors received zzso 60 zzso on Day 1 of zzso cycles, and oral zzso from Day 4 of zzso 1 at 100, 200 or 400 zzso zzso 

Common drug-related adverse events were zzso zzso zzso skin reaction zzso zzso zzso and zzso zzso The maximum tolerated dose was not zzso One patient with zzso zzso achieved a partial response zzso WHO zzso and remained on therapy for zzso zzso Fifteen patients zzso achieved stable disease for zzso zzso zzso exposure increased moderately with zzso 400 zzso zzso The zzso of zzso and zzso were not zzso 

zzso 400 zzso bid plus zzso 60 zzso was well zzso The increased zzso exposure with zzso 400 zzso bid did not result in significantly increased zzso low patient numbers make the clinical significance of this zzso These promising efficacy results justify further clinical zzso 

